Biofocus and the Usher III Initiative have announced a drug discovery project focused on Usher Syndrome Type III.
Usher Syndrome is a rare genetic disorder that causes loss of hearing and vision.
Under the agreement, Biofocus will perform an integrated programme encompassing medicinal chemistry and biological sciences.
'We will support the Usher III Initiative in its aim to find a targeted treatment and cure for Usher III,' said Angus MacLeod, vice-president, medicinal chemistry, Biofocus.
